Tripti Shrivastava
Overview
Explore the profile of Tripti Shrivastava including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
565
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Garg S, Raj N, Lukose A, Jamwal D, Parray H, Kumar S, et al.
3 Biotech
. 2022 Aug;
12(9):202.
PMID: 35928502
Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-022-03272-6.
12.
Chiranjivi A, Kumar D, Kumar R, Parray H, Ahmed S, Kumar C, et al.
Int J Biol Macromol
. 2022 Jul;
217:19-26.
PMID: 35817240
Dengue virus is transmitted by Aedes mosquitoes and dengue is endemic in many regions of the world. Severe dengue results in complications that may lead to death. Although some vaccine...
13.
Vikkurthi R, Ansari A, Pai A, Jha S, Sachan S, Pandit S, et al.
Nat Microbiol
. 2022 Jun;
7(7):974-985.
PMID: 35681012
BBV152 is a whole-virion inactivated vaccine based on the Asp614Gly variant. BBV152 is the first alum-imidazoquinolin-adjuvanted vaccine authorized for use in large populations. Here we characterized the magnitude, quality and...
14.
Rizvi Z, Dalal R, Sadhu S, Binayke A, Dandotiya J, Kumar Y, et al.
Elife
. 2022 Jan;
11.
PMID: 35014610
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the Golden Syrian hamster causes lung pathology that resembles human coronavirus disease (COVID-19). However, extrapulmonary pathologies associated with SARS-CoV-2 infection and post-COVID...
15.
Thiruvengadam R, Awasthi A, Medigeshi G, Bhattacharya S, Mani S, Sivasubbu S, et al.
Lancet Infect Dis
. 2021 Nov;
22(4):473-482.
PMID: 34838183
Background: SARS-CoV-2 variants of concern (VOCs) have threatened COVID-19 vaccine effectiveness. We aimed to assess the effectiveness of the ChAdOx1 nCoV-19 vaccine, predominantly against the delta (B.1.617.2) variant, in addition...
16.
Perween R, PraveenKumar M, Shrivastava T, Parray H, Singh V, Singh S, et al.
Int Immunopharmacol
. 2021 Oct;
101(Pt B):108187.
PMID: 34649114
Cross-reactivity among the two diverse viruses is believed to originate from the concept of antibodies recognizing similar epitopes on the two viral surfaces. Cross-reactive antibody responses have been seen in...
17.
Murugavelu P, Perween R, Shrivastava T, Singh V, Parray H, Singh S, et al.
Int Immunopharmacol
. 2021 Aug;
99:108020.
PMID: 34426117
The spike protein of the SARS-CoV-2 virus is the foremost target for the designing of vaccines and therapeutic antibodies and also acts as a crucial antigen in the assessment of...
18.
Parray H, Shukla S, Perween R, Khatri R, Shrivastava T, Singh V, et al.
Appl Microbiol Biotechnol
. 2021 Aug;
105(16-17):6315-6332.
PMID: 34423407
The route of administration of a therapeutic agent has a substantial impact on its success. Therapeutic antibodies are usually administered systemically, either directly by intravenous route, or indirectly by intramuscular...
19.
Gupta A, Anand A, Jain N, Goswami S, Anantharaj A, Patil S, et al.
Mol Ther Nucleic Acids
. 2021 Jun;
26:321-332.
PMID: 34188971
The recent SARS-CoV-2 outbreak has been declared a global health emergency. It will take years to vaccinate the whole population to protect them from this deadly virus, hence the management...
20.
Shrivastava T, Singh B, Rizvi Z, Verma R, Goswami S, Vishwakarma P, et al.
Front Immunol
. 2021 Jun;
12:641447.
PMID: 34108961
The newly emerged novel coronavirus, SARS-CoV-2, the causative agent of COVID-19 has proven to be a threat to the human race globally, thus, vaccine development against SARS-CoV-2 is an unmet...